ascendis
pharma
appoints
mark
bach
senior
vice
president
clinical
development
medical
affairs
endocrinology
rare
diseases
copenhagen
denmark
globe
newswire
ascendis
pharma
nasdaq
asnd
biopharmaceutical
company
utilizes
innovative
technologies
address
unmet
medical
needs
today
announced
appointed
mark
bach
senior
vice
president
clinical
development
medical
affairs
endocrinology
rare
diseases
excited
welcome
mark
ascendis
pharma
proven
track
record
building
global
clinical
development
medical
affairs
organizational
capabilities
bringing
new
medicines
patients
worldwide
said
jan
mikkelsen
president
ceo
ascendis
pharma
mark
joining
us
critical
time
investigational
product
pipeline
rapidly
advancing
expertise
help
advance
potential
transformative
therapies
people
rare
endocrine
exciting
time
join
ascendis
pharma
company
prepares
potential
launch
first
rare
endocrinology
disease
product
pediatric
growth
hormone
deficiency
works
improve
healthcare
people
endocrine
rare
diseases
said
bach
look
forward
helping
ascendis
pharma
build
upon
strong
foundational
transcon
technology
platform
bring
innovative
therapies
forward
address
unmet
patient
bach
pediatric
endocrinologist
years
experience
clinical
research
development
extensive
global
experience
building
leading
clinical
teams
successfully
launched
innovative
pharmaceutical
products
global
markets
recently
served
head
asia
pacific
medical
sciences
janssen
pharmaceutical
co
prior
janssen
vice
president
clinical
research
operations
worldwide
merck
bach
recognized
expert
endocrinology
research
lectured
widely
national
international
forums
served
numerous
professional
society
advisory
boards
advance
field
endocrinology
clinical
research
published
extensively
including
dozens
original
research
articles
review
articles
scientific
abstracts
bach
received
medical
degree
baylor
college
medicine
houston
texas
doctorate
degree
university
chicago
illinois
bachelor
degree
carleton
college
northfield
minnesota
technology
transcon
refers
transient
proprietary
transcon
platform
innovative
technology
designed
create
new
therapies
optimize
therapeutic
effect
including
efficacy
safety
dosing
frequency
transcon
molecules
three
components
unmodified
parent
drug
inert
carrier
protects
linker
temporarily
binds
two
bound
carrier
inactivates
shields
parent
drug
clearance
injected
body
physiologic
conditions
ph
temperature
initiate
release
active
unmodified
parent
drug
predictable
manner
parent
drug
unmodified
original
mode
action
may
maintained
transcon
technology
designed
applied
broadly
protein
peptide
small
molecule
multiple
therapeutic
areas
used
systemically
locally
ascendis
pharma
ascendis
pharma
applying
innovative
platform
technology
build
leading
fully
integrated
biopharma
company
focused
making
meaningful
difference
patients
lives
guided
core
values
patients
science
passion
company
utilizes
technologies
create
new
potentially
therapies
ascendis
pharma
currently
pipeline
three
independent
endocrinology
rare
disease
product
candidates
clinical
development
advancing
oncology
second
therapeutic
area
focus
company
continues
expand
additional
therapeutic
areas
address
unmet
patient
needs
ascendis
headquartered
copenhagen
denmark
additional
offices
heidelberg
berlin
germany
palo
alto
redwood
city
california
information
please
visit
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
included
press
release
regarding
ascendis
future
operations
plans
objectives
management
statements
examples
statements
include
limited
statements
relating
ascendis
preparations
potential
launch
first
rare
endocrinology
disease
product
pediatric
growth
hormone
deficiency
ii
ascendis
work
improve
healthcare
people
endocrine
rare
diseases
iii
ascendis
ability
apply
platform
technology
build
leading
fully
integrated
biopharma
company
iv
ascendis
product
pipeline
expansion
additional
therapeutic
areas
v
ascendis
expectations
regarding
ability
utilize
transcon
technologies
create
new
potentially
therapies
ascendis
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
statements
ascendis
makes
including
following
unforeseen
safety
efficacy
results
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
unforeseen
expenses
related
development
potential
commercialization
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
selling
general
administrative
expenses
research
development
expenses
ascendis
business
generally
delays
development
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
related
manufacturing
regulatory
requirements
speed
patient
recruitment
unforeseen
delays
dependence
third
party
manufacturers
supply
study
drug
planned
clinical
studies
ascendis
ability
obtain
additional
funding
needed
support
business
activities
effects
business
worldwide
pandemic
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
well
risks
relating
ascendis
business
general
see
ascendis
prospectus
supplement
filed
july
ascendis
current
future
reports
filed
submitted
securities
exchange
commission
sec
including
annual
report
form
filed
sec
april
statements
reflect
potential
impact
future
collaborations
acquisitions
mergers
dispositions
joint
ventures
investments
ascendis
may
enter
make
ascendis
assume
obligation
update
statements
except
required
law
ascendis
ascendis
pharma
ascendis
pharma
logo
company
logo
transcon
trademarks
owned
ascendis
pharma
group
november
ascendis
pharma
investor
contacts
media
contact
tim
lee
ron
rogers
ascendis
pharma
ascendis
pharma
tle
patti
bank
westwicke
partners
ir
